Naomi Fujioka
Expertise in
16
conditions

Dr. Naomi Fujioka

Hematology | Otolaryngology | Oncology
M Health Fairview University Of Minnesota Medical Center
2312 S 6th St, Ste F-275, 
Minneapolis, MN 
Accepting New Patients
Offers Telehealth
Expertise in
16
conditions
M Health Fairview University Of Minnesota Medical Center
2312 S 6th St, Ste F-275, 
Minneapolis, MN 

Overview

Naomi Fujioka is a Hematologist and an Otolaryngologist practicing medicine in Minneapolis, Minnesota.

Dr. Fujioka is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Endoscopy.

Dr. Fujioka is board certified in Internal Medicine: American Board Of Internal Medicine, 2007 and Medical Oncology: American Board Of Internal Medicine, 2010. She is actively involved in clinical research, co-authoring 39 peer reviewed articles and participating in 5 clinical trials. Dr. Fujioka is currently accepting new patients.

Residency

University of Minnesota - Internal Medicine, Internal Medicine - 2007

Specialties

Hematology
Otolaryngology
Oncology

Licenses

Internal Medicine in MN

Board Certifications

Internal Medicine: American Board Of Internal Medicine, 2007
Medical Oncology: American Board Of Internal Medicine, 2010

Fellowships

University of Minnesota-Hematology and Oncology, Hematology/Oncology - 2011

Hospital Affiliations

Fairview Lakes Health Services
M Health Fairview University Of Mn Medical Center
M Health Fairview Southdale Hospital
M Health Fairview Ridges Hospital
M Health Fairview St John's Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Group Health Cooperative
  • HMO
  • POS
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Metropolitan Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PreferredOne
  • HMO
  • OTHER COMMERCIAL
Sanford Health
  • HMO
  • PPO
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

M Health Fairview University Of Minnesota Medical Center
2312 S 6th St, Ste F-275, Minneapolis, MN 55454
Other Locations
M Health Fairview Clinical Research Unit
516 Delaware Street Southeast, Floor 1, Minneapolis, MN 55455
M Health Fairview Masonic Cancer Clinic
909 Fulton Street Southeast, Minneapolis, MN 55455

Additional Areas of Focus

Dr. Fujioka has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Enrollment Status: Completed
Publish Date: January 20, 2026
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium. BTCRC-LUN17-127
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium. BTCRC-LUN17-127
Enrollment Status: Completed
Publish Date: January 20, 2026
Intervention Type: Drug
Study Drugs: Nivolumab, Plinabulin, Ipilimumab
Study Phase: Phase 1/Phase 2
A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029
A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029
Enrollment Status: Completed
Publish Date: August 24, 2023
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug, Biological
Study Drugs: SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab
Study Phase: Phase 1
Assessing the Effect of Glucobrassicin-Rich Brussels Sprouts on the Metabolism of Deuterated Phenanthrene: Developing Food-Based Chemoprevention of Tobacco-Related Lung Cancer
Assessing the Effect of Glucobrassicin-Rich Brussels Sprouts on the Metabolism of Deuterated Phenanthrene: Developing Food-Based Chemoprevention of Tobacco-Related Lung Cancer
Enrollment Status: Completed
Publish Date: February 17, 2023
Intervention Type: Drug, Other
Study Drug: Deuterated Phenanthrene
Study Phase: Phase 1
View 4 Less Clinical Trials

39 Total Publications

Assessing the physiological relevance of the bioactivation of tobacco-specific carcinogen NNK and its metabolite NNAL: quantitative analyses of hydrolysis products from their protein adducts under different carcinogen exposure conditions.
Assessing the physiological relevance of the bioactivation of tobacco-specific carcinogen NNK and its metabolite NNAL: quantitative analyses of hydrolysis products from their protein adducts under different carcinogen exposure conditions.
Journal: Carcinogenesis
Published: February 13, 2026
Similar Doctors
Expertise in
10
conditions
Dr. Christopher L. Moertel
Hematology | Oncology
Expertise in
10
conditions
Dr. Christopher L. Moertel
Hematology | Oncology
Referral may be required

University Of Minnesota Medical Center Fairview Riverside

2450 Riverside Ave, 
Minneapolis, MN 
 (0.4 miles away)
612-365-8100
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Christopher Moertel is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Moertel is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, and RASopathies. Dr. Moertel is currently accepting new patients.

Expertise in
9
conditions
Dr. Mukta Arora
Hematology | Oncology
Expertise in
9
conditions
Dr. Mukta Arora
Hematology | Oncology
Referral may be required

Fairview Pharmacy Services LLC

516 Delaware St SE, 
Minneapolis, MN 
 (0.1 miles away)
612-273-2800
Languages Spoken:
English
See accepted insurances

Mukta Arora is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Arora is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
13
conditions
Dr. Yoav H. Messinger
Hematology | Oncology
Expertise in
13
conditions
Dr. Yoav H. Messinger
Hematology | Oncology
Referral may be required

Childrens Home Care Pharmacy

2530 Chicago Ave, 
Minneapolis, MN 
 (1.8 miles away)
612-813-5940
Languages Spoken:
English, Hebrew
See accepted insurances
Accepting New Patients

Yoav Messinger is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Messinger is highly rated in 13 conditions, according to our data. His clinical expertise encompasses DICER1 Syndrome, Sertoli-Leydig Cell Tumor, Pleuropulmonary Blastoma, Leydig Cell Testicular Tumor, and Bone Marrow Transplant. Dr. Messinger is currently accepting new patients.

Frequently Asked Questions about Dr. Naomi Fujioka

How do I make an appointment with Dr. Naomi Fujioka?

You can book an appointment with Dr. Naomi Fujioka by calling their office at 612-624-0104. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Naomi Fujioka a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Naomi Fujioka is classified as an Distinguished expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Naomi Fujioka specialize in?

While Dr. Naomi Fujioka is a Hematology, they have specific expertise in Small Cell Lung Cancer (SCLC), Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Naomi Fujioka participate in research or clinical trials?

Yes. Dr. Naomi Fujioka has published 39 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. Naomi Fujioka's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Naomi Fujioka accept my insurance?

Dr. Naomi Fujioka accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 612-624-0104 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fujioka's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 9 Advanced Conditions
    View All 39 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile